Treatment > Immunotherapy

Abstract

Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin

Grant SC, Kris MG, Houghton AN, Chapman PB

Department of Medicine, Memorial Sloan-Kettering Cancer Center and Joan and Sanford I. Weill Medical College of Cornell University, New York, New York 10021, USA

Despite active therapies for small cell lung cancer (SCLC), most patients relapse and die of the disease. 
The present study evaluates immunization using the anti-idiotypic antibody BEC2, which mimics the ganglioside GD3 expressed on the surface of most SCLC tumors, combined with Bacillus Calmette-Guerin (BCG) as an immune adjuvant. 
We hypothesized that active immunization could alter the natural history of the disease. 
Fifteen patients who had completed standard therapy for SCLC received a series of five intradermal immunizations consisting of 2.5 mg of BEC2 plus BCG over a 10-week period. 
Blood was collected for serological analysis, and outcome was monitored. 
All patients developed anti-BEC2 antibodies, despite having received chemotherapy with or without thoracic radiation. 
We detected anti-GD3 antibodies in five patients, including those with the longest relapse-free survival. 
The median relapse-free survival for patients with extensive stage disease is 11 months and has not been reached for patients with limited stage disease (>47 months), with only one of seven patients having relapsed after a median follow-up of 47 months. 
Immunization of patients with SCLC after standard therapy using BEC2 plus BCG can induce anti-GD3 antibodies and is safe. 
The survival and relapse-free survival in this group of patients are substantially better than those observed in a prior group of similar patients. 
A Phase III trial is being conducted to evaluate BEC2 plus BCG as adjuvant therapy after chemotherapy and irradiation.

PMID: 10389914 [PubMed - indexed for MEDLINE]